Objective: Although pegylated interferon α-2b (PEG-IFN α-2b) therapy for chronic hepatitis B has received increasing attention, determining the optimal treatment course remains challenging. This ...

The highest percentages of patients with HBsAg loss were observed in the groups that received xalnesiran plus an immunomodulator. The most frequent grade 3 or 4 adverse event was elevated ALT.

Methods: Serum HBV RNA, HBV DNA, hepatitis B surface antigen (HBsAg), and hepatitis B envelope antigen (HBeAg) levels were measured and compared in patients with chronic hepatitis B virus infection.

This study aimed to investigate the dynamics of peripheral blood T lymphocyte subsets during peginterferon alpha (peg-IFN-α) therapy and their association with hepatitis B surface antigen (HBsAg) ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

Chronic Hepatitis B virus (HBV) is associated with elevated levels of hepatitis B surface antigen (HBsAg). Here the authors characterize the T cell responses to three variants of an HBsAg ...

Fire crews battle the Eaton Fire on Wednesday in Altadena, Calif. (AP Photo/Ethan Swope) ...

Not only that, but they are not curative therapies by any means. These available drugs are ... 3 out of 6 patients [50%] who had baseline HBsAg <1000 IU/mL had achieved this.